Deerfield Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-145,000
| Closed | -$25M | – | 153 |
|
|
2021
Q3 | $25M | Sell |
145,000
-74,500
| -34% | -$9.74M | 0.49% | 57 |
|
|
2021
Q2 | $27.5M | Hold |
219,500
| – | – | 0.49% | 67 |
|
|
2021
Q1 | $29.8M | Sell |
219,500
-202,119
| -48% | -$26.1M | 0.63% | 53 |
|
|
2020
Q4 | $53.9M | Hold |
421,619
| – | – | 1.07% | 26 |
|
|
2020
Q3 | $47.4M | Hold |
421,619
| – | – | 1.16% | 25 |
|
|
2020
Q2 | $40.2M | Buy |
421,619
+78,619
| +23% | +$7.58M | 1.17% | 29 |
|
|
2020
Q1 | $30.8M | Sell |
343,000
-1,026,625
| -75% | -$79.8M | 0.98% | 32 |
|
|
2019
Q4 | $72.6M | Buy |
1,369,625
+64,451
| +5% | +$2.94M | 2.32% | 11 |
|
|
2019
Q3 | $51.6M | Hold |
1,305,174
| – | – | 2.1% | 11 |
|
|
2019
Q2 | $53.6M | Buy |
1,305,174
+50,000
| +4% | +$2.07M | 1.93% | 10 |
|
|
2019
Q1 | $58.5M | Sell |
1,255,174
-131,367
| -9% | -$5.77M | 2.24% | 11 |
|
|
2018
Q4 | $60.4M | Buy |
1,386,541
+268,890
| +24% | +$13.4M | 2.42% | 9 |
|
|
2018
Q3 | $64M | Sell |
1,117,651
-9,149
| -0.8% | -$450K | 2.29% | 11 |
|
|
2018
Q2 | $54.7M | Buy |
1,126,800
+511,800
| +83% | +$18.6M | 1.92% | 12 |
|
|
2018
Q1 | $24M | Hold |
615,000
| – | – | 0.83% | 46 |
|
|
2017
Q4 | $26.1M | Hold |
615,000
| – | – | 1.03% | 37 |
|
|
2017
Q3 | $23M | Buy |
+615,000
| New | +$21.3M | 1.03% | 33 |
|
|
2016
Q2 | – | Sell |
-353,491
| Closed | -$9.33M | – | 120 |
|
|
2016
Q1 | $9.33M | Buy |
353,491
+140,000
| +66% | +$4.07M | 0.4% | 60 |
|
|
2015
Q4 | $10.4M | Buy |
+213,491
| New | +$7.68M | 0.42% | 63 |
|
Deerfield Management's XLRN Position: Q4 2021 in Review
Deerfield Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 145,000 shares — an estimated $25M sold.
Deerfield Management first reported a position in XLRN in Q4 2015 and held it in 19 quarters. The position peaked at $72.6M in Q4 2019. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Deerfield Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Deerfield Management sold 145,000 Acceleron Pharma shares in Q4 2021, an estimated $25M.
- Deerfield Management first reported a position in Acceleron Pharma in Q4 2015 and held it in 19 quarters.
- Deerfield Management's Acceleron Pharma position peaked at $72.6M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.